CH1335392721
© BusinessWire
11.12.2025
GALD
LISTED
XWSX
Galderma Announces First Patient Enrollment in Study to Assess Nemolizumab in Adults With Chronic Pruritus of Unknown Origin
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase II study investigating the efficacy and safety of nemolizumab in treating patients living with Chronic Pruritus of Unknown Origin (CPUO). The first patient of the trial – which is taking place in the United States – was enrol...
Themefolio
Profiler
Peergroup
© BusinessWire
08.12.2025
GALD
LISTED
XWSX
Galderma Welcomes Increased Equity Investment From L’Oréal
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that L’Oréal Groupe intends to increase its equity investment in the company, acquiring an additional 10% stake from Sunshine SwissCo GmbH (a consortium led by EQT, Abu Dhabi Investment Authority (ADIA), and Auba Investment Pte. Ltd., acting as sellers).
Foll...
Themefolio
Profiler
Peergroup
© BusinessWire
05.12.2025
GALD
LISTED
XWSX
Galderma Opens up New Chapter for Sculptra® with MDR Certification and New Expanded Indication for Body
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the certification of Sculptra for body indications in the European Union (EU) following its certification under the EU Medical Device Regulation (MDR). This expands Sculptra’s current clinical use on the face, to include four new areas: gluteal area, posterior thighs,...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
04.12.2025
GALD
LISTED
XWSX
Galderma Secures ‘BBB’ Credit Rating With Positive Outlook from S&P Global Ratings
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that S&P Global Ratings (S&P) has assigned the company a ‘BBB’ long-term issuer credit rating with a positive outlook.
The rating reflects Galderma’s strong track record of growth and its leading positions across Injectable Aesthetics, Dermatological...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
17.11.2025
GALD
LISTED
XWSX
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Injectable Aesthetics portfolio and pipeline at the American Society for Dermatologic Surgery (ASDS) 2025 Annual Meeting, held in Chicago from November 13-16. Six poster presentations spotlighted the latest data on Restylane, Sculpt...
Themefolio
Profiler
Peergroup
© BusinessWire
05.11.2025
GALD
LISTED
XWSX
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocaine for augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versat...
Themefolio
Profiler
Peergroup
© BusinessWire
23.10.2025
GALD
LISTED
XWSX
Galderma Delivers Record Net Sales of 3.737 Billion USD in the First Nine Months of 2025 and 15.0% Year-on-Year Growth at Constant Currency, Raises Full-Year Guidance
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first nine months of 2025, delivering record net sales along with strong commercial and innovation momentum across its portfolio.
Record net sales of 3.737 billion USD for the first nine months of the year, representing net sal...
Themefolio
Profiler
Peergroup
© BusinessWire
24.09.2025
GALD
LISTED
XWSX
AMWC Dubai: Galderma Demonstrates Injectable Aesthetics Leadership Through Updates on Its Scientific Innovations and Community Education
News Preview
Galderma will present six posters with the latest updates from its science-backed aesthetic portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Dubai, United Arab Emirates, from October 1-3, 2025. The company will also showcase its leadership in aesthetic education through a number of events including a symposium and medi...
Themefolio
Profiler
Peergroup
© BusinessWire
18.09.2025
GALD
LISTED
XWSX
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay
News Preview
Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of ag...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2025
GALD
LISTED
XWSX
Galderma’s Groundbreaking Real-World Study Reveals the Biological Toll of Modern Living and Urban Environments on Sensitive Skin
News Preview
Galderma today announced new data from a first-of-its-kind real-world clinical study conducted in China assessing the biological impact of different lifestyles and their associated environmental factors on individuals with sensitive skin.1 Results from the study, conducted by dermatology experts from Galderma’s Global Sensitive Skincare Faculty (G...
Themefolio
Profiler
Peergroup
© BusinessWire
11.09.2025
GALD
LISTED
XWSX
EADV 2025: Galderma Reinforces Leadership in Dermatology With Latest Advances in Sensitive Skin and Itch
News Preview
Galderma (SIX: GALD), the dermatology category leader, today announced it will unveil updates from its portfolio at the 34th European Academy of Dermatology and Venereology (EADV) congress, taking place in Paris, September 17-20, 2025. Highlighting its commitment to addressing skin conditions across the dermatology spectrum, Galderma will present...
Themefolio
Profiler
Peergroup
© BusinessWire
10.09.2025
GALD
LISTED
XWSX
Galderma Launches Alastin® in China, Supporting the Skin’s Natural Regenerative Abilities in a Rapidly Expanding Market
News Preview
Galderma (SIX: GALD) today announced the launch of four core Alastin® products in China, marking the premium medical skincare brand’s debut in one of the world’s fastest growing aesthetic skincare markets.6-8 This is the first launch to feature Alastin by Galderma’s new re-energized, premium look and feel, a bold evolution that reflects its leader...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
24.07.2025
GALD
LISTED
XWSX
Galderma Delivers Record First Half 2025 Net Sales of 2.448 Billion USD and 12.2% Year-on-Year Growth at Constant Currency, Raises Full-Year Top-Line Guidance
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the first half of 2025.
Record net sales of 2.448 billion USD, representing net sales growth of 12.2% at constant currency, driven mainly by volume and complemented by favorable mix
Double-digit growth in both International mark...
Themefolio
Profiler
Peergroup
© BusinessWire
17.07.2025
GALD
LISTED
XWSX
Galderma Unveils Final Nine-Month Data Showing Lasting Efficacy and Patient Satisfaction With Its Injectable Aesthetics Portfolio When Addressing Facial Aesthetic Changes After Medication-Driven Weight Loss
News Preview
Galderma has revealed positive final data from a phase IV first-of-its-kind trial exploring the benefits of Restylane Lyft or Contour in combination with Sculptra to address the aesthetic concerns of patients experiencing facial volume loss associated with medication-driven weight loss.1 These data reinforce that this treatment regimen can effecti...
Themefolio
Profiler
Peergroup
© BusinessWire
01.07.2025
GALD
LISTED
XWSX
Galderma Announces Departure of Its Chief Financial Officer
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced that Thomas Dittrich, Chief Financial Officer, will be leaving the company to pursue another senior executive opportunity outside the organization.
“We thank Thomas for his financial leadership and many contributions during his time at Galderma. He p...
Themefolio
Profiler
Peergroup
© BusinessWire
25.06.2025
GALD
LISTED
XWSX
Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need.1-3,7
Nemolizumab is...
Themefolio
Profiler
Peergroup
© BusinessWire
18.06.2025
GALD
LISTED
XWSX
ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years
News Preview
Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during p...
Themefolio
Profiler
Peergroup
© BusinessWire
12.06.2025
GALD
LISTED
XWSX
Galderma’s Nemluvio® (nemolizumab) Receives National Institute for Health and Care Excellence (NICE) Recommendation for Moderate-to-severe Atopic Dermatitis in England and Wales
News Preview
Galderma today announced that nemolizumab has been recommended for routine funding on the National Health Service in England and Wales for moderate-to-severe atopic dermatitis in final draft guidance from the National Institute for Health and Care Excellence.1 This follows its recent marketing authorisation by the United Kingdom (UK) Medicines and...
Themefolio
Profiler
Peergroup
© BusinessWire
06.06.2025
GALD
LISTED
XWSX
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years
News Preview
Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The data show that Nemluvio is well tolerated, with no new safety signals identified, reinforcing its rapid onset of action and demonstrating sustai...
Themefolio
Profiler
Peergroup
© BusinessWire
28.05.2025
GALD
LISTED
XWSX
Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering
News Preview
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it has agreed to repurchase 2.38 million shares at a price of CHF 97.75 per share for a total consideration of CHF 232.5 million in the context of the accelerated bookbuild offering (“ABO”) of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment...
Themefolio
Profiler
Peergroup
© BusinessWire
27.05.2025
GALD
LISTED
XWSX
Galderma Intends to Buy Back approximately 2.4 Million Shares in the Context of the Accelerated Bookbuild Offering by EQT, ADIA and Auba
News Preview
Galderma Group AG (SWX:GALD):
Ad hoc announcement pursuant to Art. 53 LR
Galderma intends to repurchase approximately 2.4 million shares in the context of the accelerated bookbuild offering of Galderma shares by Sunshine SwissCo GmbH (“EQT”), Abu Dhabi Investment Authority (“ADIA”) and Auba Investment Pte. Ltd. (“Auba”) announced today
The...
Themefolio
Profiler
Peergroup
© BusinessWire
24.04.2025
GALD
LISTED
XWSX
Galderma Delivers Record First Quarter Net Sales of 1.129 Billion USD, Including Strong Performance From Two Launches With Blockbuster Potential, and Confirms Full-Year Guidance
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2025.
Net sales: Achieved 1,129 million USD in net sales, up 8.3% year-on-year on a constant currency basis, primarily driven by volume, complemented by favorable mix
Results ahead of expectations: Net sales b...
Themefolio
Profiler
Peergroup
© BusinessWire
17.04.2025
GALD
LISTED
XWSX
Galderma launches new ALASTIN Restorative Skin Complex with Next Generation TriHex Technology®
News Preview
Galderma Group AG (SWX:GALD), the pure-play dermatology category leader, announced today that ALASTIN, a leader in medical-grade peptide-based regenerative skincare, has officially launched their latest skincare innovation with the introduction of Restorative Skin Complex with Next Generation TriHex Technology® (TriHex+™). This newly enhanced form...
Themefolio
Profiler
Peergroup
© BusinessWire
15.04.2025
GALD
LISTED
XWSX
Galderma Launches Sculptra® in China, Further Fueling Its Growth Into One of the Fastest Growing Aesthetics Markets
News Preview
Galderma today announced the launch of Sculptra, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation, in China.1-7,11-14 This follows Sculptra’s approval by China’s National Medical Products Administration for correcting mid-facial volume loss and/or contour deficiencies last year. Sculptra – which...
Themefolio
Profiler
Peergroup
© BusinessWire
20.03.2025
GALD
LISTED
XWSX
AMWC 2025: Galderma Pushes the Innovation Frontier With Updates From Its Unparalleled Portfolio Designed to Meet the Needs of the Aesthetic Community
News Preview
Galderma (SWX:GALD) will showcase a strong presence at the 23rd Aesthetic & Anti-Aging Medicine World Congress (AMWC) in Monaco from March 27-29, 2025, with two symposia, four Masterclass sessions, 11 research e-posters, and an experiential Galderma lounge alongside its interactive booth (O2, Hall Ravel) featuring five Meet-the-Expert sessions...
Themefolio
Profiler
Peergroup
© BusinessWire
06.03.2025
GALD
LISTED
XWSX
Galderma Delivers 2024 Record Net Sales of 4.410 Billion USD, up 9.3% Year-on-Year at Constant Currency1, and Record Core EBITDA of 1.031 Billion USD, While Preparing to Accelerate Its Growth Trajectory Into 2025 and Beyond
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its financial results for the full year 2024, delivering strong results for another consecutive year while making significant progress with its blockbuster platforms and future growth drivers.
Record net sales: Achieved 4,410 million USD in net sales, up 9.3...
Themefolio
Profiler
Peergroup
© BusinessWire
03.03.2025
GALD
LISTED
XWSX
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum
News Preview
Galderma will present updates from across its broad dermatology portfolio at the 2025 American Academy of Dermatology (AAD) Annual Meeting, taking place from March 7-11, 2025 in Orlando, Florida. The company will present 22 e-posters – including two oral presentations – with updates on a number of its innovative products, including Nemluvio, Sculp...
Themefolio
Profiler
Peergroup
© BusinessWire
18.02.2025
GALD
LISTED
XWSX
Galderma’s Nemluvio® (Nemolizumab) Granted Marketing Authorization in the United Kingdom and Switzerland for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
News Preview
Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedic have granted the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the UK and Switzerland, respectively. Specifically, the approvals are for nemolizumab’s subcutaneous us...
Themefolio
Profiler
Peergroup
© BusinessWire
14.02.2025
GALD
LISTED
XWSX
Galderma’s Nemluvio® (Nemolizumab) Approved in the European Union for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis
News Preview
Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is now approved for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for sys...
Themefolio
Profiler
Peergroup
© BusinessWire
31.01.2025
GALD
LISTED
XWSX
IMCAS 2025: New Galderma Phase IIIb Data Reinforce Rapid Onset and Long-lasting Aesthetic Improvement with RelabotulinumtoxinA (Relfydess™)
News Preview
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today results from its new phase IIIb RELAX clinical trial demonstrating the rapid onset and the long-lasting duration of aesthetic efficacy, as well as high patient satisfaction and increased confidence, using a single-dose of RelabotulinumtoxinA (Relfydess) to treat frown...
Themefolio
Profiler
Peergroup
© BusinessWire
30.01.2025
GALD
LISTED
XWSX
Galderma Demonstrates Injectable Aesthetics Leadership in Medication-Driven Weight Loss With New Research and First International Consensus-Based Guidelines
News Preview
Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven weight loss on the skin and the importance of factoring in aesthetic treatment goals during the patient’s journey, as well as the first international consensus-based guidelines from global experts on how to treat this patient popula...
Themefolio
Profiler
Peergroup
© BusinessWire
23.01.2025
GALD
LISTED
XWSX
IMCAS 2025: Galderma’s Broad Presence and New Data on Recently Launched Products Restylane® SHAYPE™ and Relfydess® Reaffirm Its Category Leadership
News Preview
Galderma will present the latest updates from its innovative aesthetics portfolio at the International Master Course on Aging Science (IMCAS) World Congress 2025 on January 30 – February 1 in Paris, France. The company will share ten research e-posters with data that differentiate its injectable aesthetic products, including Relfydess (Relabotulin...
Themefolio
Profiler
Peergroup
© BusinessWire
14.01.2025
GALD
LISTED
XWSX
Galderma Premieres Positive Interim Results Demonstrating the Efficacy of Its Injectable Aesthetics Portfolio in Addressing Facial Volume Loss as a Result of Medication-driven Weight Loss
News Preview
Galderma (SWX:GALD) announces positive first results from a trial designed to explore the benefits of Restylane® Lyft™ or Contour™ in combination with Sculptra® in patients with medication-driven weight loss with associated facial volume loss.1 Initial three-month interim data from this first-of-its-kind trial suggest that this treatment combinati...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
GALD
LISTED
XWSX
Galderma Receives U.S. FDA Approval for Nemluvio® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis
News Preview
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequatel...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
GALD
LISTED
XWSX
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union
News Preview
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemo...
Themefolio
Profiler
Peergroup
© BusinessWire
28.11.2024
GALD
LISTED
XWSX
Galderma’s Phase III OLYMPIA 1 Data Published in JAMA Dermatology Demonstrate That Nemolizumab Improves Core Signs and Symptoms of Prurigo Nodularis
News Preview
Galderma (SWX:GALD) today announced that full results from the phase III OLYMPIA 1 trial, a 24-week study which evaluated the efficacy and safety of nemolizumab monotherapy in adults with moderate-to-severe prurigo nodularis, were published in JAMA Dermatology.1 The trial met both primary and all key secondary endpoints, showing that nemolizumab-t...
Themefolio
Profiler
Peergroup
© BusinessWire
04.11.2024
GALD
LISTED
XWSX
Celebrating 25 Years of Sculptra®: New Data and Recent Approval in China Cements Galderma’s Leadership in Regenerative Biostimulation
News Preview
This month marks the 25th anniversary of the approval of Sculptra®, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation.1-5,10-16 Sculptra works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance, and has been a cornerstone of Galderma’s broad portfol...
Themefolio
Profiler
Peergroup
© BusinessWire
25.10.2024
GALD
LISTED
XWSX
Galderma Brings Together Over 650 Healthcare Professionals from Asia-Pacific to Elevate Knowledge of Future Aesthetic Trends
News Preview
Galderma (SWX:GALD), the pure-play dermatology category leader, today announced a new edition of the Galderma Aesthetic Injector Network (GAIN) event in the Asia-Pacific region, which houses some of the company’s fastest growing markets. This is the largest regional event to date and will deliver a premium and engaging experience for more than 650...
Themefolio
Profiler
Peergroup
© BusinessWire
24.10.2024
GALD
LISTED
XWSX
Galderma Delivers Record Net Sales of 3.259 B USD in the First Nine Months of 2024, Demonstrates Significant Innovation Progress, Confirms and Narrows Its Full Year Net Sales Guidance
News Preview
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2024, reporting record net sales and significant progress across its product categories and key future growth drivers.
Record net sales: Achieved 3.259 billion USD in net sales during the first nine months o...
Themefolio
Profiler
Peergroup
© BusinessWire
21.10.2024
GALD
LISTED
XWSX
ASDS 2024: New Phase III READY-4 Data Demonstrate Long-Term Safety and Efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™)
News Preview
Galderma today announced new phase III data from the READY-4 clinical trial, demonstrating the long-term safety of RelabotulinumtoxinA (Relfydess™) for frown lines and crow’s feet after repeated injections.1 The READY-4 study met its primary and secondary endpoints, with less than one in five participants experiencing treatment-related treatment-e...
Themefolio
Profiler
Peergroup
© BusinessWire
25.09.2024
GALD
LISTED
XWSX
EADV 2024 Late Breaking News Sessions: New Galderma Data Demonstrating Nemolizumab’s Long-term Efficacy and Safety in Atopic Dermatitis and Durability in Prurigo Nodularis to Be Shared During Three Oral Presentations
News Preview
Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and prurigo nodularis, respectively, at the 2024 European Academy of Dermatology and Venereology (EADV) congress in Amsterdam during three separate oral presentations. These late-breaking data w...
Themefolio
Profiler
Peergroup
© BusinessWire
17.09.2024
GALD
LISTED
XWSX
Galderma Reaffirms Its Leadership in Dermatology With Extensive Presence at EADV 2024
News Preview
Galderma (SWX:GALD), the pure-play dermatology category leader, announced today it will be showcasing updates from across its industry-leading dermatology portfolio at the 33rd European Academy of Dermatology and Venereology (EADV) congress taking place in Amsterdam, September 25-28, 2024, reinforcing its commitment to advancing dermatology for ev...
Themefolio
Profiler
Peergroup
© BusinessWire
13.08.2024
GALD
LISTED
XWSX
Galderma Receives U.S. FDA Approval for Nemluvio® (nemolizumab) for Adult Patients Living With Prurigo Nodularis
News Preview
Galderma today announced that the U.S. Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) as a pre-filled pen for subcutaneous injection for the treatment of adults with prurigo nodularis.1 Nemluvio was granted Breakthrough Therapy Designation in December 2019 and Priority Review in February 2024 by the U.S. FDA – a status res...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
